Advanced

Resistens mot acetylsalicylsyra - klinisk diagnos utan klarlagd mekanism

Hillarp, Andreas LU (2004) In Läkartidningen 101(45). p.3504-3509
Abstract
A review on the subject of aspirin resistance and its role in vascular diseases is presented. Although the clinical diagnosis of aspirin resistance is frequently made, little is known about its biochemical background. Only a few follow-up studies, with varying design, have dealt with the possible association between an aspirin resistant phenotype and clinical outcome in patients with atherothrombosis. However, it was recently shown that ibuprofen acts as a competitive inhibitor in the blockage of COX-1. This pharmacodynamic interaction results in secondary aspirin resistance, which may have clinical significance in patients taking both medicines. With the complex nature of vascular diseases in mind, it is not surprising that aspirin used... (More)
A review on the subject of aspirin resistance and its role in vascular diseases is presented. Although the clinical diagnosis of aspirin resistance is frequently made, little is known about its biochemical background. Only a few follow-up studies, with varying design, have dealt with the possible association between an aspirin resistant phenotype and clinical outcome in patients with atherothrombosis. However, it was recently shown that ibuprofen acts as a competitive inhibitor in the blockage of COX-1. This pharmacodynamic interaction results in secondary aspirin resistance, which may have clinical significance in patients taking both medicines. With the complex nature of vascular diseases in mind, it is not surprising that aspirin used as a single preventive strategy fails in many cases. At present, there is no clear evidence that treatment failure is associated with a particular aspirin resistant phenotype. (Less)
Please use this url to cite or link to this publication:
author
organization
alternative title
Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Platelet Aggregation Inhibitors: metabolism, Platelet Aggregation: drug effects, Ibuprofen: metabolism, Ibuprofen: pharmacology, Humans, Phenotype, Fibrinolytic Agents: pharmacology, Fibrinolytic Agents: metabolism, English Abstract, Drug Tolerance: genetics, Drug Resistance: genetics, Drug Interactions, Cyclooxygenase Inhibitors: pharmacology, Cyclooxygenase Inhibitors: metabolism, Cardiovascular Diseases: metabolism, Cardiovascular Diseases: drug therapy, Bleeding Time, Aspirin: metabolism, Aspirin: pharmacology, Platelet Aggregation Inhibitors: pharmacology
in
Läkartidningen
volume
101
issue
45
pages
3504 - 3509
publisher
Swedish Medical Association
external identifiers
  • scopus:8844255583
ISSN
0023-7205
language
Swedish
LU publication?
yes
id
c94b2ddf-edd4-4046-a8cd-161d5151674b (old id 132192)
alternative location
http://ltarkiv.lakartidningen.se/artNo29369
date added to LUP
2007-07-25 11:38:16
date last changed
2017-01-01 06:43:19
@article{c94b2ddf-edd4-4046-a8cd-161d5151674b,
  abstract     = {A review on the subject of aspirin resistance and its role in vascular diseases is presented. Although the clinical diagnosis of aspirin resistance is frequently made, little is known about its biochemical background. Only a few follow-up studies, with varying design, have dealt with the possible association between an aspirin resistant phenotype and clinical outcome in patients with atherothrombosis. However, it was recently shown that ibuprofen acts as a competitive inhibitor in the blockage of COX-1. This pharmacodynamic interaction results in secondary aspirin resistance, which may have clinical significance in patients taking both medicines. With the complex nature of vascular diseases in mind, it is not surprising that aspirin used as a single preventive strategy fails in many cases. At present, there is no clear evidence that treatment failure is associated with a particular aspirin resistant phenotype.},
  author       = {Hillarp, Andreas},
  issn         = {0023-7205},
  keyword      = {Platelet Aggregation Inhibitors: metabolism,Platelet Aggregation: drug effects,Ibuprofen: metabolism,Ibuprofen: pharmacology,Humans,Phenotype,Fibrinolytic Agents: pharmacology,Fibrinolytic Agents: metabolism,English Abstract,Drug Tolerance: genetics,Drug Resistance: genetics,Drug Interactions,Cyclooxygenase Inhibitors: pharmacology,Cyclooxygenase Inhibitors: metabolism,Cardiovascular Diseases: metabolism,Cardiovascular Diseases: drug therapy,Bleeding Time,Aspirin: metabolism,Aspirin: pharmacology,Platelet Aggregation Inhibitors: pharmacology},
  language     = {swe},
  number       = {45},
  pages        = {3504--3509},
  publisher    = {Swedish Medical Association},
  series       = {Läkartidningen},
  title        = {Resistens mot acetylsalicylsyra - klinisk diagnos utan klarlagd mekanism},
  volume       = {101},
  year         = {2004},
}